 |
 |
 |
 |
 |
 |
|
 |
 |
 |
LEADERSHIP COMPANY OVERVIEW BOARD OF DIRECTORS WEB BASED RESOURCES SCIENTIFIC ADVISORY BOARD |
 |
Leadership Martin J. Driscoll Mr. Driscoll became CEO of Javelin in March 2008 and brings more than twenty-five years of executive experience in pharmaceutical Marketing & Sales, Business Development and Operations to the company. Mr. Driscoll joined Javelin from Pear Tree Pharmaceuticals, a private pharmaceutical company focused on developing prescription products for women, prior to Pear Tree, Mr. Driscoll was a principal of MJD Consulting LLC, a commercial and management consulting firm for the pharmaceutical industry. Until August of 2005, Mr. Driscoll was Senior Vice President of Marketing and Sales at Reliant Pharmaceuticals, a privately-held company that markets a portfolio of branded pharmaceutical products, where he was a member of the Management Committee and an Executive Officer of the Company. Prior to joining Reliant, Mr. Driscoll was Vice President of Commercial Operations and Business Development at ViroPharma Inc. Mr. Driscoll was also the ViroPharma Chair for the ViroPharma/Aventis Joint Steering Committee for the companies' antiviral product collaboration. From 1983 to 2000, Mr. Driscoll held positions of increasing responsibility at the Schering-Plough Corporation, including Vice President of Marketing and Sales for Schering's Primary Care, Diabetes, Acute Coronary Syndromes, and Key Pharmaceuticals Units. His experience includes management of franchises that encompass oncologic, cardiovascular, anti-infective, metabolic, CNS, pulmonary and dermatologic products. His extensive experience includes the negotiation, implementation and management of collaborations with other life sciences companies from both the licensor and licensee perspective. Mr. Driscoll is a graduate of the University of Texas in Austin, TX.
Daniel B. Carr, MD Daniel B. Carr, M.D was appointed President in June 2008 and has been Chief Medical Officer of Javelin since 2004. He is also the Saltonstall Professor of Pain Research in the Departments of Anesthesia and Medicine at Tufts Medical Center and also a founding director of the MS Program in Pain Research, Education & Policy of Tufts University School of Medicine. He is known internationally for his contributions to pain research, evidence-based pain medicine, and to the social and political aspects of pain relief. He co-chaired and drafted major portions of the Agency for Health Care Policy and Research Clinical Practice Guidelines on Acute and Cancer Pain Management, and has edited and authored over 300 articles and books spanning clinical practice, literature syntheses, and narrative medicine; systematic reviews in peer-reviewed publications. Dr. Carr is also the recipient of many awards and honors from leading professional organizations and healthcare institutions worldwide. Dr. Carr received an MD with Honors (Alpha Omega Alpha) as well as MS and BS (Honors) degrees in Physics from Columbia University.
Fred H. Mermelstein, PhD Dr. Mermelstein is the founder of Pain Management, Inc., now Javelin Pharmaceuticals and has served on the Board of Directors since its inception. Dr. Mermelstein has worked in various roles at the company including CEO and President. Formerly, Dr. Mermelstein served as Director of Venture Capital for Paramount Capital Investments, LLC., where he was also a General Partner of the of Orion Biomedical GP, LLC and has served on the New York Biotechnology Association’s Advisory Committee. He also serves as Chairman of Pear Tree Pharmaceuticals and Director of Adherex Technologies, Inc.; and previously Cardiome Pharma and the Jordan Heart Foundation. From February 1997 until January 2000, Dr. Mermelstein was the founder and has served as a Director and Chief Science Officer of PolaRx BioPharmaceuticals, an oncology-based biopharmaceutical company which developed Trisenox™. Dr. Mermelstein holds a dual PhD in Pharmacology and Toxicology from Rutgers University and University of Medicine and Dentistry of New Jersey (UMDNJ) Robert Wood Johnson Medical School. He completed his post-doctoral training supported by two grant awards; a National Institutes of Health fellowship and a Howard Hughes Medical Institute fellowship in the Department of Biochemistry at UMDNJ Robert Wood Johnson Medical School. Dr. Mermelstein has authored numerous publications and several patents.
Stephen J. Tulipano, CPA, MBA Stephen J. Tulipano joined Javelin in May 2006 as its Chief Financial Officer. In this capacity, he oversees all of the Company's finance functions, including treasury, tax, accounting, financial planning, reporting, controls and Sarbanes-Oxley compliance. Previously, he was Director of Corporate Accounting at Biogen Idec. During his tenure at Biogen Idec, which spanned over seven years, he was responsible for accounting, external reporting, establishment of new accounting and internal control initiatives worldwide and developing innovative business approaches to partnered programs and business development opportunities. Prior to joining Biogen, he served as External Reporting Manager for Digital Equipment Corporation. Mr. Tulipano is a Certified Public Accountant, a member of the American Institute of Certified Public Accountants (AICPA) and the Massachusetts Society of Certified Public Accountants and holds a M.B.A. from Suffolk University. He is also a veteran of the United States Navy and the United States Army National Guard. Frederick E. Pierce, II Mr. Pierce has been the Company's Vice President of Investor Relations since July 2006. Prior to that he was Interim CEO of GlycoGenesys, Inc. from February 2006 until June 2006. Prior to his role as interim CEO, he was GlycoGenesys' Vice President of Business Development since 2002 and the company's Vice President of Finance and Investor Relations from June 1998. Prior to joining GlycoGenesys Mr. Pierce had 12 years experience working in Wall Street firms representing and/or advising major biotechnology and medical device companies. From 1994 to 1997, Mr. Pierce was at Lehman Brothers, where he was the New England private client services liaison to healthcare investment banking. Prior thereto, Mr. Pierce had over seven years experience in portfolio management and brokerage and institutional equity sales at Kidder Peabody and Merrill Lynch.
Eric Lang, MD Dr. Eric Lang joined Javelin in October 2008 as its Vice President of Clinical Research, bringing over fifteen years of experience in clinical development, regulatory affairs, scientific licensing and drug / device development experience to the Company; with a particular focus in the areas of Pain and CNS. Dr. Lang comes from Novartis, where he was most recently the Global Head of Clinical Research and Development for Analgesia for its Consumer Health Division. In that role, he was responsible for the design and implementation of the clinical strategy for its global analgesics franchise. Dr. Lang was a member of the team which obtained US FDA regulatory approval for Novartis' Voltaren Sodium Gel(R) (topical diclofenac sodium) in 2007, the first topical NSAID approved in the USA for osteoarthritis Prior to Novartis, Dr. Lang held roles of increasing responsibility at Johnson & Johnson for seven years. Dr. Lang received his medical degree at Ben Gurion University of the Negev in Beer Sheba, Israel and completed an acute and chronic pain fellowship at Emory University Medical School.
|
|
